scout
|Videos|September 1, 2020

KRAS-Mutant NSCLC

Advancements in drugs targeting KRAS G12C mutations and incorporating AMG 510 and MRTX849 into clinical practice when treating mNSCLC.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME